Potential cancer-related role of circadian gene TIMELESS suggested by expression profiling and in vitro analyses

BMC Cancer

Volumn 13, Issue , 2013, Pages

  Mao, Yingying ^a,b   Fu, Alan ^b   Leaderer, Derek ^b   Zheng, Tongzhang ^b   Chen, Kun ^a   Zhu, Yong ^b  

^a ZHEJIANG UNIVERSITY   (China)

^b YALE UNIVERSITY   (United States)

Author keywords

Cell cycle; Circadian gene; Expression profiling; TIMELESS; Tumorigenesis

Indexed keywords

PROTEIN TIMELESS; SMALL INTERFERING RNA;

ADVANCED CANCER; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER PROGNOSIS; CANCER STAGING; CANCER SUSCEPTIBILITY; CARCINOGENESIS; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE FREQUENCY; GENE FUNCTION; GENE IDENTIFICATION; GENE OVEREXPRESSION; GENETIC TRANSCRIPTION; IN VITRO STUDY; MICROARRAY ANALYSIS; NUCLEOTIDE SEQUENCE; TIMELESS GENE; UTERINE CERVIX CANCER;

BREAST NEOPLASMS; CELL CYCLE PROTEINS; CELL LINE, TUMOR; CELL PROLIFERATION; CIRCADIAN RHYTHM; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKDOWN TECHNIQUES; GENE REGULATORY NETWORKS; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; NEOPLASM STAGING; NEOPLASMS; PROGNOSIS;

EID: 84886232132     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-13-498     Document Type: Article

References (65)

1. Young MW, Kay SA. Time zones: a comparative genetics of circadian clocks. Nat Rev Genet 2001, 2:702-715. 10.1038/35088576, 11533719.
2. Ko CH, Takahashi JS. Molecular components of the mammalian circadian clock. Hum Mol Genet 2006, 15(2):R271-R277.
3. Sclafani RA, Holzen TM. Cell cycle regulation of DNA replication. Annu Rev Genet 2007, 41:237-280. 10.1146/annurev.genet.41.110306.130308, 2292467, 17630848.
4. Sancar A, Lindsey-Boltz LA, Unsal-Kacmaz K, Linn S. Molecular mechanisms of mammalian DNA repair and the DNA damage checkpoints. Annu Rev Biochem 2004, 73:39-85. 10.1146/annurev.biochem.73.011303.073723, 15189136.
5. Levi F, Filipski E, Iurisci I, Li XM, Innominato P. Cross-talks between circadian timing system and cell division cycle determine cancer biology and therapeutics. Cold Spring Harb Symp Quant Biol 2007, 72:465-475. 10.1101/sqb.2007.72.030, 18419306.
6. Bjarnason GA, Jordan R. Circadian variation of cell proliferation and cell cycle protein expression in man: clinical implications. Prog Cell Cycle Res 2000, 4:193-206.
7. Unsal-Kacmaz K, Mullen TE, Kaufmann WK, Sancar A. Coupling of human circadian and cell cycles by the timeless protein. Mol Cell Biol 2005, 25:3109-3116. 10.1128/MCB.25.8.3109-3116.2005, 1069621, 15798197.
8. Dheekollu J, Wiedmer A, Hayden J, Speicher D, Gotter AL, Yen T, Lieberman PM. Timeless links replication termination to mitotic kinase activation. PLoS One 2011, 6:e19596. 10.1371/journal.pone.0019596, 3089618, 21573113.
9. Yang XM, Wood PA, Hrushesky WJM. Mammalian TIMELESS Is Required for ATM-dependent CHK2 Activation and G(2)/M Checkpoint Control. J Biol Chem 2010, 285:3030-3034. 10.1074/jbc.M109.050237, 2823431, 19996108.
10. Stevens RG. Circadian disruption and breast cancer: from melatonin to clock genes. Epidemiology 2005, 16:254-258. 10.1097/01.ede.0000152525.21924.54, 15703542.
11. Stevens RG, Rea MS. Light in the built environment: potential role of circadian disruption in endocrine disruption and breast cancer. Canc Causes Control 2001, 12:279-287.
12. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000, 100:57-70. 10.1016/S0092-8674(00)81683-9, 10647931.
13. Fu A, Leaderer D, Zheng T, Hoffman AE, Stevens RG, Zhu Y. Genetic and epigenetic associations of circadian gene TIMELESS and breast cancer risk. Mol Carcinog 2011, 51(12):923-929.
14. Mazzoccoli G, Panza A, Valvano MR, Palumbo O, Carella M, Pazienza V, Biscaglia G, Tavano F, Di Sebastiano P, Andriulli A, Piepoli A. Clock gene expression levels and relationship with clinical and pathological features in colorectal cancer patients. Chronobiol Int 2011, 28:841-851. 10.3109/07420528.2011.615182, 22080729.
15. Lin YM, Chang JH, Yeh KT, Yang MY, Liu TC, Lin SF, Su WW, Chang JG. Disturbance of circadian gene expression in hepatocellular carcinoma. Mol Carcinog 2008, 47:925-933. 10.1002/mc.20446, 18444243.
16. Rhodes DR, Yu J, Shanker K, Deshpande N, Varambally R, Ghosh D, Barrette T, Pandey A, Chinnaiyan AM. ONCOMINE: a cancer microarray database and integrated data-mining platform. Neoplasia 2004, 6:1-6. 1635162, 15068665.
17. Fischer-Doetzkies E, Georg J. [Shift-work management in nursing]. Pflege Aktuell 2005, 59:72-75.
18. Zhai Y, Kuick R, Nan B, Ota I, Weiss SJ, Trimble CL, Fearon ER, Cho KR. Gene expression analysis of preinvasive and invasive cervical squamous cell carcinomas identifies HOXC10 as a key mediator of invasion. Canc Res 2007, 67:10163-10172.
19. Cheng AS, Culhane AC, Chan MW, Venkataramu CR, Ehrich M, Nasir A, Rodriguez BA, Liu J, Yan PS, Quackenbush J, et al. Epithelial progeny of estrogen-exposed breast progenitor cells display a cancer-like methylome. Canc Res 2008, 68:1786-1796.
20. Sreekumar A, Poisson LM, Rajendiran TM, Khan AP, Cao Q, Yu J, Laxman B, Mehra R, Lonigro RJ, Li Y, et al. Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression. Nature 2009, 457:910-914. 10.1038/nature07762, 2724746, 19212411.
21. Taylor BS, Schultz N, Hieronymus H, Gopalan A, Xiao Y, Carver BS, Arora VK, Kaushik P, Cerami E, Reva B, et al. Integrative genomic profiling of human prostate cancer. Canc Cell 2010, 18:11-22.
22. Carroll JS, Meyer CA, Song J, Li W, Geistlinger TR, Eeckhoute J, Brodsky AS, Keeton EK, Fertuck KC, Hall GF, et al. Genome-wide analysis of estrogen receptor binding sites. Nat Genet 2006, 38:1289-1297. 10.1038/ng1901, 17013392.
23. Ringner M, Fredlund E, Hakkinen J, Borg A, Staaf J. GOBO: gene expression-based outcome for breast cancer online. PLoS One 2011, 6:e17911. 10.1371/journal.pone.0017911, 3061871, 21445301.
24. Calvano SE, Xiao W, Richards DR, Felciano RM, Baker HV, Cho RJ, Chen RO, Brownstein BH, Cobb JP, Tschoeke SK, et al. A network-based analysis of systemic inflammation in humans. Nature 2005, 437:1032-1037. 10.1038/nature03985, 16136080.
25. Benjamini Y, Hochberg Y. Controlling the false discovery rate - a practical and powerful approach to multiple testing. J Roy Stat Soc Ser B Meth 1995, 57:289-300.
26. Cheng WL, Wang CS, Huang YH, Tsai MM, Liang Y, Lin KH. Overexpression of CXCL1 and its receptor CXCR2 promote tumor invasion in gastric cancer. Ann Oncol 2011, 22:2267-2276. 10.1093/annonc/mdq739, 21343381.
27. Kim TH, Xiong H, Zhang Z, Ren B. Beta-Catenin activates the growth factor endothelin-1 in colon cancer cells. Oncogene 2005, 24:597-604. 10.1038/sj.onc.1208237, 15558022.
28. Bangoura G, Liu ZS, Qian Q, Jiang CQ, Yang GF, Jing S. Prognostic significance of HIF-2alpha/EPAS1 expression in hepatocellular carcinoma. World J Gastroenterol 2007, 13:3176-3182.
29. Mohammed N, Rodriguez M, Garcia V, Garcia JM, Dominguez G, Pena C, Herrera M, Gomez I, Diaz R, Soldevilla B, et al. EPAS1 mRNA in plasma from colorectal cancer patients is associated with poor outcome in advanced stages. Oncol Lett 2011, 2:719-724. 3406439, 22848255.
30. Wallin U, Glimelius B, Jirstrom K, Darmanis S, Nong RY, Ponten F, Johansson C, Pahlman L, Birgisson H. Growth differentiation factor 15: a prognostic marker for recurrence in colorectal cancer. Br J Canc 2011, 104:1619-1627.
31. Staff AC, Trovik J, Eriksson AG, Wik E, Wollert KC, Kempf T, Salvesen HB. Elevated plasma growth differentiation factor-15 correlates with lymph node metastases and poor survival in endometrial cancer. Clin Canc Res 2011, 17:4825-4833.
32. Xie K. Interleukin-8 and human cancer biology. Cytokine Growth Factor Rev 2001, 12:375-391. 10.1016/S1359-6101(01)00016-8, 11544106.
33. Benoy IH, Salgado R, Van Dam P, Geboers K, Van Marck E, Scharpe S, Vermeulen PB, Dirix LY. Increased serum interleukin-8 in patients with early and metastatic breast cancer correlates with early dissemination and survival. Clin Canc Res 2004, 10:7157-7162.
34. Depianto D, Kerns ML, Dlugosz AA, Coulombe PA. Keratin 17 promotes epithelial proliferation and tumor growth by polarizing the immune response in skin. Nat Genet 2010, 42:910-914. 10.1038/ng.665, 2947596, 20871598.
35. Economescu MC, Necula LG, Dragu D, Badea L, Dima SO, Tudor S, Nastase A, Popescu I, Diaconu CC. Identification of potential biomarkers for early and advanced gastric adenocarcinoma detection. Hepatogastroenterology 2010, 57:1453-1464.
36. Kim YH, Kwei KA, Girard L, Salari K, Kao J, Pacyna-Gengelbach M, Wang P, Hernandez-Boussard T, Gazdar AF, Petersen I, et al. Genomic and functional analysis identifies CRKL as an oncogene amplified in lung cancer. Oncogene 2010, 29:1421-1430. 10.1038/onc.2009.437, 3320568, 19966867.
37. Padmanabhan RA, Nirmala L, Murali M, Laloraya M. CrkL is a co-activator of estrogen receptor alpha that enhances tumorigenic potential in cancer. Mol Endocrinol 2011, 25:1499-1512. 10.1210/me.2011-0008, 21700719.
38. Baraniskin A, Birkenkamp-Demtroder K, Maghnouj A, Zollner H, Munding J, Klein-Scory S, Reinacher-Schick A, Schwarte-Waldhoff I, Schmiegel W, Hahn SA. MiR-30a-5p suppresses tumor growth in colon carcinoma by targeting DTL. Carcinogenesis 2012, 33(4):732-739. 10.1093/carcin/bgs020, 22287560.
39. Sossey-Alaoui K, Kitamura E, Cowell JK. Fine mapping of the PTGFR gene to 1p31 region and mutation analysis in human breast cancer. Int J Mol Med 2001, 7:543-546.
40. Cho HS, Toyokawa G, Daigo Y, Hayami S, Masuda K, Ikawa N, Yamane Y, Maejima K, Tsunoda T, Field HI, et al. The JmjC domain-containing histone demethylase KDM3A is a positive regulator of the G(1)/S transition in cancer cells via transcriptional regulation of the HOXA1 gene. Int J Canc 2011, 131(3):E179-E189.
41. Chevillard S, Ugolin N, Vielh P, Ory K, Levalois C, Elliott D, Clayman GL, El-Naggar AK. Gene expression profiling of differentiated thyroid neoplasms: diagnostic and clinical implications. Clin Canc Res 2004, 10:6586-6597.
42. Riker AI, Enkemann SA, Fodstad O, Liu S, Ren S, Morris C, Xi Y, Howell P, Metge B, Samant RS, et al. The gene expression profiles of primary and metastatic melanoma yields a transition point of tumor progression and metastasis. BMC Med Genom 2008, 1:13.
43. Papatriantafyllou M. Tumour immunology: TSLP drives human tumour progression. Nat Rev Immunol 2011, 11:235. 10.1038/nri2961, 21553711.
44. Bravard A, Sabatier L, Hoffschir F, Ricoul M, Luccioni C, Dutrillaux B. SOD2: a new type of tumor-suppressor gene?. Int J Canc 1992, 51:476-480.
45. Liu X, Wang A, Lo Muzio L, Kolokythas A, Sheng S, Rubini C, Ye H, Shi F, Yu T, Crowe DL, Zhou X. Deregulation of manganese superoxide dismutase (SOD2) expression and lymph node metastasis in tongue squamous cell carcinoma. BMC Canc 2010, 10:365.
46. Zhou J, Zhu Y, Zhang G, Liu N, Sun L, Liu M, Qiu M, Luo D, Tang Q, Liao Z, et al. A distinct role of RhoB in gastric cancer suppression. Int J Canc 2011, 128:1057-1068.
47. Huang M, Prendergast GC. RhoB in cancer suppression. Histol Histopathol 2006, 21:213-218.
48. Welch C, Santra MK, El-Assaad W, Zhu XC, Huber WE, Keys RA, Teodoro JG, Green MR. Identification of a protein, G0S2, that lacks Bcl-2 homology domains and Interacts with and antagonizes Bcl-2. Canc Res 2009, 69:6782-6789.
49. Zhang J, Cao W, Xu Q, Chen WT. The expression of EMP1 is downregulated in oral squamous cell carcinoma and possibly associated with tumour metastasis. J Clin Pathol 2011, 64:25-29. 10.1136/jcp.2010.082404, 20980531.
50. Jensen SM, Maston LD, Gough MI, Ruby CE, Redmond WL, Crittenden M, Li YH, Puri S, Poehlein CH, Morris N, et al. Signaling through OX40 enhances antitumor immunity. Semin Oncol 2010, 37:524-532. 10.1053/j.seminoncol.2010.09.013, 2997672, 21074068.
51. Buglio D, Khaskhely NM, Voo KS, Martinez-Valdez H, Liu YJ, Younes A. HDAC11 plays an essential role in regulating OX40 ligand expression in Hodgkin lymphoma. Blood 2011, 117:2910-2917. 10.1182/blood-2010-08-303701, 3062301, 21239696.
52. Braidotti P, Nuciforo PG, Mollenhauer J, Poustka A, Pellegrini C, Moro A, Bulfamante G, Coggi G, Bosari S, Pietra GG. DMBT1 expression is down-regulated in breast cancer. BMC Canc 2004, 4. http://www.biomedcentral.com/1471-2407/4/46.
53. Du J, Guan M, Fan J, Jiang H. Loss of DMBT1 expression in human prostate cancer and its correlation with clinical progressive features. Urology 2011, 77(509):e509-e513.
54. Cho YG, Chang X, Park IS, Yamashita K, Shao C, Ha PK, Pai SI, Sidransky D, Kim MS. Promoter methylation of leukemia inhibitory factor receptor gene in colorectal carcinoma. Int J Oncol 2011, 39:337-344. 3601031, 21617854.
55. Ribarska T, Ingenwerth M, Goering W, Engers R, Schulz WA. Epigenetic inactivation of the placentally imprinted tumor suppressor gene TFPI2 in prostate carcinoma. Canc Genom Proteomics 2010, 7:51-60.
56. Fox BP, Kandpal RP. EphB6 receptor significantly alters invasiveness and other phenotypic characteristics of human breast carcinoma cells. Oncogene 2009, 28:1706-1713. 10.1038/onc.2009.18, 19234485.
57. Hoffman AE, Zheng T, Stevens RG, Ba Y, Zhang Y, Leaderer D, Yi C, Holford TR, Zhu Y. Clock-cancer connection in non-Hodgkin's lymphoma: a genetic association study and pathway analysis of the circadian gene cryptochrome 2. Canc Res 2009, 69:3605-3613.
58. Hoffman AE, Yi CH, Zheng T, Stevens RG, Leaderer D, Zhang Y, Holford TR, Hansen J, Paulson J, Zhu Y. CLOCK in breast tumorigenesis: genetic, epigenetic, and transcriptional profiling analyses. Canc Res 2010, 70:1459-1468.
59. Mollenhauer J, Herbertz S, Holmskov U, Tolnay M, Krebs I, Merlo A, Schroder HD, Maier D, Breitling F, Wiemann S, et al. DMBT1 encodes a protein involved in the immune defense and in epithelial differentiation and is highly unstable in cancer. Canc Res 2000, 60:1704-1710.
60. Motoyama K, Tanaka F, Kosaka Y, Mimori K, Uetake H, Inoue H, Sugihara K, Mori M. Clinical significance of BMP7 in human colorectal cancer. Ann Surg Oncol 2008, 15:1530-1537. 10.1245/s10434-007-9746-4, 18259822.
61. Schwalbe M, Sanger J, Eggers R, Naumann A, Schmidt A, Hoffken K, Clement JH. Differential expression and regulation of bone morphogenetic protein 7 in breast cancer. Int J Oncol 2003, 23:89-95.
62. Strelau J, Schmeer C, Peterziel H, Sackmann T, Herold-Mende C, Steiner H, Weller M, Unsicker K. Expression and putative functions of GDF-15, a member of the TGF-beta superfamily, in human glioma and glioblastoma cell lines. Canc Lett 2008, 270:30-39.
63. Yuan A, Chen JJ, Yao PL, Yang PC. The role of interleukin-8 in cancer cells and microenvironment interaction. Front Biosci 2005, 10:853-865. 10.2741/1579, 15569594.
64. Gotter AL, Suppa C, Emanuel BS. Mammalian TIMELESS and Tipin are evolutionarily conserved replication fork-associated factors. J Mol Biol 2007, 366:36-52. 10.1016/j.jmb.2006.10.097, 17141802.
65. Yoshizawa-Sugata N, Masai H. Human Tim/Timeless-interacting protein, Tipin, is required for efficient progression of S phase and DNA replication checkpoint. J Biol Chem 2007, 282:2729-2740.